Gene-specific somatic epigenetic mosaicism of FDFT1 underlies a non-hereditary localized form of porokeratosis.

FDFT1 cholesterol clonal expansion epigenetic mosaicism germline variant mevalonate pathway porokeratosis promoter hypermethylation somatic variant statin

Journal

American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475

Informations de publication

Date de publication:
10 Apr 2024
Historique:
received: 19 12 2023
revised: 12 03 2024
accepted: 28 03 2024
medline: 24 4 2024
pubmed: 24 4 2024
entrez: 23 4 2024
Statut: aheadofprint

Résumé

Porokeratosis is a clonal keratinization disorder characterized by solitary, linearly arranged, or generally distributed multiple skin lesions. Previous studies showed that genetic alterations in MVK, PMVK, MVD, or FDPS-genes in the mevalonate pathway-cause hereditary porokeratosis, with skin lesions harboring germline and lesion-specific somatic variants on opposite alleles. Here, we identified non-hereditary porokeratosis associated with epigenetic silencing of FDFT1, another gene in the mevalonate pathway. Skin lesions of the generalized form had germline and lesion-specific somatic variants on opposite alleles in FDFT1, representing FDFT1-associated hereditary porokeratosis identified in this study. Conversely, lesions of the solitary or linearly arranged localized form had somatic bi-allelic promoter hypermethylation or mono-allelic promoter hypermethylation with somatic genetic alterations on opposite alleles in FDFT1, indicating non-hereditary porokeratosis. FDFT1 localization was uniformly diminished within the lesions, and lesion-derived keratinocytes showed cholesterol dependence for cell growth and altered expression of genes related to cell-cycle and epidermal development, confirming that lesions form by clonal expansion of FDFT1-deficient keratinocytes. In some individuals with the localized form, gene-specific promoter hypermethylation of FDFT1 was detected in morphologically normal epidermis adjacent to methylation-related lesions but not distal to these lesions, suggesting that asymptomatic somatic epigenetic mosaicism of FDFT1 predisposes certain skin areas to the disease. Finally, consistent with its genetic etiology, topical statin treatment ameliorated lesions in FDFT1-deficient porokeratosis. In conclusion, we identified bi-allelic genetic and/or epigenetic alterations of FDFT1 as a cause of porokeratosis and shed light on the pathogenesis of skin mosaicism involving clonal expansion of epigenetically altered cells.

Identifiants

pubmed: 38653249
pii: S0002-9297(24)00115-0
doi: 10.1016/j.ajhg.2024.03.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests T.T. and M.I. are employees of Japan Tissue Engineering Co., Ltd.

Auteurs

Sonoko Saito (S)

Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Yuki Saito (Y)

Department of Gastroenterology, Keio University School of Medicine, Tokyo 160-8582, Japan; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.

Showbu Sato (S)

Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Satomi Aoki (S)

Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Harumi Fujita (H)

Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Yoshihiro Ito (Y)

Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Noriko Ono (N)

Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Takeru Funakoshi (T)

Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Tomoko Kawai (T)

Department of Maternal-Fetal Biology, National Center for Child Health and Development, Tokyo 157-8535, Japan.

Hisato Suzuki (H)

Center for Medical Genetics, Keio University School of Medicine, Tokyo 160-8582, Japan.

Takashi Sasaki (T)

Center for Supercentenarian Medical Research, Keio University School of Medicine, Tokyo 160-8582, Japan.

Tomoyo Tanaka (T)

R&D department, Japan Tissue Engineering Co., Ltd., Aichi 443-0022, Japan.

Masukazu Inoie (M)

R&D department, Japan Tissue Engineering Co., Ltd., Aichi 443-0022, Japan.

Kenichiro Hata (K)

Department of Maternal-Fetal Biology, National Center for Child Health and Development, Tokyo 157-8535, Japan; Department of Human Molecular Genetics, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan.

Keisuke Kataoka (K)

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo 104-0045, Japan; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.

Kenjiro Kosaki (K)

Center for Medical Genetics, Keio University School of Medicine, Tokyo 160-8582, Japan.

Masayuki Amagai (M)

Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Kazuhiko Nakabayashi (K)

Department of Maternal-Fetal Biology, National Center for Child Health and Development, Tokyo 157-8535, Japan. Electronic address: nakabaya-k@ncchd.go.jp.

Akiharu Kubo (A)

Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan; Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Hyogo 650-0017, Japan. Electronic address: akiharu@keio.jp.

Classifications MeSH